Dermapharm Holding SE (DMP.DE)

EUR 36.6

(0.27%)

EBITDA Summary of Dermapharm Holding SE

Dermapharm Holding SE's latest annual EBITDA in 2023 was 277.29 Million EUR , down -7.19% from previous year.
Dermapharm Holding SE's latest quarterly EBITDA in 2024 Q2 was 64.06 Million EUR , down -33.39% from previous quarter.
Dermapharm Holding SE reported an annual EBITDA of 329.81 Million EUR in 2022, down -5.66% from previous year.
Dermapharm Holding SE reported an annual EBITDA of 358.1 Million EUR in 2021, up 82.71% from previous year.
Dermapharm Holding SE reported a quarterly EBITDA of 88.44 Million EUR for 2024 Q1, up 46.28% from previous quarter.
Dermapharm Holding SE reported a quarterly EBITDA of 74.51 Million EUR for 2023 Q3, up 63.77% from previous quarter.

Annual EBITDA Chart of Dermapharm Holding SE (2023 - 2014)

Historical Annual EBITDA of Dermapharm Holding SE (2023 - 2014)

Year	EBITDA	EBITDA Growth
2023	277.29 Million EUR	-7.19%
2022	329.81 Million EUR	-5.66%
2021	358.1 Million EUR	82.71%
2020	186.56 Million EUR	12.41%
2019	172.19 Million EUR	20.76%
2018	134.12 Million EUR	25.76%
2017	110.43 Million EUR	5.76%
2016	105.54 Million EUR	11.62%
2015	89.3 Million EUR	25.89%
2014	74.19 Million EUR	0.0%

Year	EBITDA	EBITDA Growth
2024 Q2	64.06 Million EUR	-33.39%
2024 Q1	88.44 Million EUR	46.28%
2023 Q3	74.51 Million EUR	63.77%
2023 Q4	65.95 Million EUR	-11.49%
2023 FY	- EUR	-7.19%
2023 Q1	98.51 Million EUR	1.1%
2023 Q2	45.49 Million EUR	-53.82%
2022 Q1	72.43 Million EUR	-40.97%
2022 FY	- EUR	-5.66%
2022 Q2	71.33 Million EUR	-1.51%
2022 Q4	97.44 Million EUR	9.05%
2022 Q3	89.36 Million EUR	25.27%
2021 Q4	122.7 Million EUR	24.75%
2021 FY	- EUR	82.71%
2021 Q2	74.26 Million EUR	18.04%
2021 Q3	98.35 Million EUR	32.44%
2021 Q1	62.91 Million EUR	21.31%
2020 Q4	51.85 Million EUR	11.73%
2020 FY	- EUR	12.41%
2020 Q3	46.41 Million EUR	26.64%
2020 Q2	36.65 Million EUR	-25.89%
2020 Q1	49.45 Million EUR	15.35%
2019 Q2	43.11 Million EUR	5.6%
2019 FY	- EUR	20.76%
2019 Q1	40.82 Million EUR	11.38%
2019 Q4	42.87 Million EUR	-3.81%
2019 Q3	44.57 Million EUR	3.38%
2018 Q4	36.65 Million EUR	1.94%
2018 FY	- EUR	25.76%
2018 Q2	33.5 Million EUR	-6.45%
2018 Q1	35.81 Million EUR	40.12%
2018 Q3	35.95 Million EUR	7.33%
2017 Q2	27.93 Million EUR	-4.54%
2017 Q3	28.95 Million EUR	3.66%
2017 Q1	29.25 Million EUR	12.03%
2017 FY	- EUR	5.76%
2017 Q4	25.55 Million EUR	-11.72%
2016 FY	- EUR	11.62%
2016 Q4	26.11 Million EUR	0.0%
2015 FY	- EUR	25.89%
2014 FY	- EUR	0.0%

Peer EBITDA Comparison of Dermapharm Holding SE

Name	EBITDA	EBITDA Difference
MPH Health Care AG	33.31 Million EUR	-732.372%
Apontis Pharma AG	-12.94 Million EUR	2242.716%
Evotec SE	7.82 Million EUR	-3444.625%
MERCK Kommanditgesellschaft auf Aktien	5.52 Billion EUR	94.977%
PharmaSGP Holding SE	35.86 Million EUR	-673.101%
SynBiotic SE	-7.12 Million EUR	3993.186%